A Phase 3 interventional study of pregabalin 600 mg/day and pregabalin 150 mg/day in Epilepsies, Partial, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 73 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-20.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing pregabalin in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Pregabalin · Epilepsies, Partial.
Among the 18 studies testing pregabalin in Epilepsies, Partial, this one is the 11th largest by enrollment, is one of 5 that started in 2007, is one of 12 in phase 3, and was the 12th registered.
243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.
Browse Epilepsies, Partial studies →None of the 18 studies testing pregabalin in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 12 · Phase 4 4
First in 1997; this study’s year is marked. 5 started in 2007.
This study's enrollment of 161 is above the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.
Median enrollment 244 across the 18 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 18 have an industry lead sponsor. The 3 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
15 studies in Epilepsies, Partial by Viatris Inc.: none open now, none under way, none of them phase 3. Of 15 finished, 15 (100%) have results posted.
Among the 15 studies in Epilepsies, Partial by Viatris Inc., this one is the 6th largest by enrollment of the 13 interventional ones that give a count, is one of 7 that started in 2007, is one of 8 in phase 3, and was the 6th registered.
Viatris Inc.’s Epilepsies, Partial studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing pregabalin in Epilepsies, Partial, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 15 in Epilepsies, Partial:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will determine the safety and efficacy of pregabalin (Lyrica) when administered by itself (without any other anti-epileptic medication) to epilepsy subjects for the treatment of partial seizures. The duration of the trial is about 6 months.
After review of the interim analysis results, the independent Data Monitoring Committee (DMC) recommended to stop the study based on positive efficacy findings for the primary efficacy endpoint according to pre-specified stopping rules. Pfizer accepted the DMC recommendation and made the decision to stop the study on September 7, 2011.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: pregabalin 600 mg/day
Drug: pregabalin 150 mg/day
Drug page: Pregabalin
pregabalin 600 mg/day (300mg BID), duration is 20 weeks.
Drug page: Pregabalin
pregabalin 150 mg/day (75mg BID), duration is 20 weeks.
Percentage of Participants in the Pregabalin 600 mg/Day Treatment Group Discontinuing the Study Due to at Least 1 Pre-Defined Seizure Exit Criteria
Participants who discontinued due to: episode of status epilepticus (SE); secondarily generalized tonic-clonic (SGTC) seizure if none within 2 years of study entry; 28-day study seizure rate during double-blind phase (DBP) greater than (\>)2 times maximum (Max) 28-day study seizure rate during baseline phase (BLP); 2-day study seizure rate during DBP \>2 times Max 2-day study seizure rate during BLP; or unacceptable clinically significant increase in frequency/intensity of seizure activity. Determined as exit rate:(1-Kaplan-Meier \[KM\] product limit estimate for survival function) \* 100%
Time frame: Week 2 up to Week 18
Percentage of Participants in the Pregabalin 150 mg/Day Treatment Group Discontinuing the Study Due to at Least 1 Pre-Defined Seizure Exit Criteria
Participants who discontinued due to: episode of SE; SGTC seizure if none within 2 years of study entry; 28-day study seizure rate during DBP \>2 times Max 28-day study seizure rate during BLP; 2-day study seizure rate during DBP \>2 times Max 2-day study seizure rate during BLP; or unacceptable clinically significant increase in frequency/intensity of seizure activity. Determined as exit rate, defined as (1-KM product limit estimate for survival function) \* 100%
Time frame: Week 2 up to Week 18
Percentage of Participants Completing 20 Weeks of Double-Blind Treatment
Time frame: Randomization up to Week 20
Percentage of Participants Who Met Protocol-Specified Exit Events
Percentage of participants experiencing any of the following (could have had more than 1): 1) episode of SE; 2) SGTC seizure if none had been experienced within 2 years of study entry; 3) 28-day study seizure rate during DBP \>2 times the Max 28-day study seizure rate during BLP; 4) 2-day study seizure rate during the DBP \>2 times the Max 2-day study seizure rate during BLP; or 5) unacceptable clinically significant increase in frequency/intensity of seizure activity
Time frame: Week 2 up to Week 18
Mean Time on Pregabalin Monotherapy
Time frame: Week 2 to Week 20
Percentage of Seizure-Free Participants by Study Phase
Percentage of participants who were seizure-free during the last 28 days on double-blind study medication (monotherapy phase, Days 112-140), during the monotherapy portion of the double-blind treatment phase (Days 56-140), and during all of the double-blind treatment phase (Days 1-140)
Time frame: Day 1 up to Day 140
Pregabalin Population Pharmacokinetics (PK)
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Time frame: Baseline up to 20 weeks
Pregabalin Exposure-Response Analysis
Percentage of participants predicted to exit the study due to any seizure exit criteria at Day 126. The exit rate at Day 126 was predicted using the final model (log normal distribution with respect to treatment group) and the parameter estimates.
Time frame: Day 126
| Milestone | Pregabalin 150 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|
| Started | 32 | 129 |
| Completed double-blind treatment phase | 15 | 70 |
| Completed taper/titration phase | 15 | 70 |
| Completed | 15 | 70 |
| Not completed | 17 | 59 |
| Withdrew: Lack of efficacy | 10 | 24 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Withdrawal by subject | 3 | 8 |
| Withdrew: Noncompliance/investigator discretion | 0 | 2 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Adverse event | 3 | 21 |
| Withdrew: Death | 0 | 1 |
Participants who discontinued due to: episode of status epilepticus (SE); secondarily generalized tonic-clonic (SGTC) seizure if none within 2 years of study entry; 28-day study seizure rate during double-blind phase (DBP) greater than (\>)2 times maximum (Max) 28-day study seizure rate during baseline phase (BLP); 2-day study seizure rate during DBP \>2 times Max 2-day study seizure rate during BLP; or unacceptable clinically significant increase in frequency/intensity of seizure activity. Determined as exit rate:(1-Kaplan-Meier \[KM\] product limit estimate for survival function) \* 100%
| Percentage of Participants | Pregabalin 600 mg/Day |
|---|---|
| Percentage of Participants in the Pregabalin 600 mg/Day Treatment Group Discontinuing the Study Due to at Least 1 Pre-Defined Seizure Exit Criteria | 31.9 (20.7 to 43.1) |
Participants who discontinued due to: episode of SE; SGTC seizure if none within 2 years of study entry; 28-day study seizure rate during DBP \>2 times Max 28-day study seizure rate during BLP; 2-day study seizure rate during DBP \>2 times Max 2-day study seizure rate during BLP; or unacceptable clinically significant increase in frequency/intensity of seizure activity. Determined as exit rate, defined as (1-KM product limit estimate for survival function) \* 100%
| Percentage of Participants | Pregabalin 150 mg/Day |
|---|---|
| Percentage of Participants in the Pregabalin 150 mg/Day Treatment Group Discontinuing the Study Due to at Least 1 Pre-Defined Seizure Exit Criteria | 37.7 (15.4 to 60) |
| Percentage of Participants | Pregabalin 150 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|
| Percentage of Participants Completing 20 Weeks of Double-Blind Treatment | 53.6 | 58.3 |
Percentage of participants experiencing any of the following (could have had more than 1): 1) episode of SE; 2) SGTC seizure if none had been experienced within 2 years of study entry; 3) 28-day study seizure rate during DBP \>2 times the Max 28-day study seizure rate during BLP; 4) 2-day study seizure rate during the DBP \>2 times the Max 2-day study seizure rate during BLP; or 5) unacceptable clinically significant increase in frequency/intensity of seizure activity
| Percentage of Participants | Pregabalin 150 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|
| Status Epilepticus | 0 | 1.0 |
| SGTC Seizure (not experienced in previous 2 years) | 0 | 2.9 |
| 28-Day Seizure Rate >2 times Max Baseline Rate | 13.0 | 10.8 |
| 2-Day Seizure Rate >2 times Max Baseline Rate | 13.0 | 7.8 |
| Increased Frequency/Intensity of Seizure Activity | 17.4 | 14.7 |
| Total | 39.1 | 28.4 |
| Days | Pregabalin 150 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|
| Mean Time on Pregabalin Monotherapy | 73.8 ± 30.15 | 78.0 ± 28.24 |
Percentage of participants who were seizure-free during the last 28 days on double-blind study medication (monotherapy phase, Days 112-140), during the monotherapy portion of the double-blind treatment phase (Days 56-140), and during all of the double-blind treatment phase (Days 1-140)
| Percentage of Participants | Pregabalin 150 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|
| Last 28 Days of Monotherapy (Days 112-140) | 17.9 | 12.5 |
| Monotherapy (Days 56-140) | 7.1 | 6.7 |
| Entire Double-Blind Treatment (Days 1-140) | 0 | 1.7 |
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
No measurements were reported for this outcome.
Percentage of participants predicted to exit the study due to any seizure exit criteria at Day 126. The exit rate at Day 126 was predicted using the final model (log normal distribution with respect to treatment group) and the parameter estimates.
| Percentage of Participants | Pregabalin 150 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|
| Pregabalin Exposure-Response Analysis | 37.2 | 26.3 |
Collected over Baseline to Week 21. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin 150 mg/Day | — | 1/32 (3.1%) | 15/32 (46.9%) |
| Pregabalin 600 mg/Day | — | 17/129 (13.2%) | 75/129 (58.1%) |
| Event | Pregabalin 150 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|
| ConvulsionNervous system disorders | 0/32 | 5/129 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/32 | 0/129 |
| PneumoniaInfections and infestations | 0/32 | 2/129 |
| Grand mal convulsionNervous system disorders | 0/32 | 2/129 |
| Angina pectorisCardiac disorders | 0/32 | 1/129 |
| Cardio-respiratory arrestCardiac disorders | 0/32 | 1/129 |
| Abdominal painGastrointestinal disorders | 0/32 | 1/129 |
| Chest painGeneral disorders | 0/32 | 1/129 |
| Meningitis bacterialInfections and infestations | 0/32 | 1/129 |
| Complex partial seizuresNervous system disorders | 0/32 | 1/129 |
| Event | Pregabalin 150 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|
| DizzinessNervous system disorders | 5/32 | 25/129 |
| SomnolenceNervous system disorders | 5/32 | 22/129 |
| Weight increasedInvestigations | 2/32 | 21/129 |
| FatigueGeneral disorders | 2/32 | 20/129 |
| HeadacheNervous system disorders | 0/32 | 13/129 |
| Disturbance in attentionNervous system disorders | 3/32 | 4/129 |
| Dry mouthGastrointestinal disorders | 2/32 | 2/129 |
| Alanine aminotransferase increasedInvestigations | 2/32 | 1/129 |
| DysarthriaNervous system disorders | 2/32 | 2/129 |
| Vision blurredEye disorders | 1/32 | 8/129 |
| Age, Continuous(years) | Pregabalin 150 mg/Day | Pregabalin 600 mg/Day | Total |
|---|---|---|---|
| Mean | 35.2 ± 12.4 | 39.9 ± 13.2 | 39.0 ± 13.2 |
| Sex: Female, Male(Participants) | Pregabalin 150 mg/Day | Pregabalin 600 mg/Day | Total |
|---|---|---|---|
| Female | 18 | 71 | 89 |
| Male | 14 | 58 | 72 |
The record gives a start of Sep 2007, a primary completion of Apr 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
Results were first posted in May 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →